David Amsellem

Sr. Research Analyst
Sector Expertise
Additional Expertise
David Amsellem is a managing director and senior research analyst at Piper Sandler covering pharmaceuticals. Amsellem has more than 20 years of Wall Street experience focused on the biopharmaceuticals space, with experience in life sciences investment and merchant banking prior to moving to the sell-side. Prior to joining Piper Sandler in 2008, Amsellem spent five years at Friedman Billings Ramsey, where he was a senior research analyst covering small- and mid-cap pharmaceuticals from 2006-2008 and a senior associate on the biotechnology equity research team from 2003-2006. Amsellem earned a Bachelor of Science degree from Cornell University.

Universe Coverage

ALKSAlkermes Plc
AMRXAmneal Pharmaceuticals Inc.
AMPHAmphastar Pharmaceuticals, Inc.
AQSTAquestive Therapeutics, Inc.
AVDLAvadel Pharmaceuticals plc
AXSMAxsome Therapeutics, Inc.
BHCBausch Health Companies
CARACara Therapeutics Inc.
CERECerevel Therapeutics Holdings, Inc.
COLLCollegium Pharmaceutical, Inc.
CORTCorcept Therapeutics Inc.
HRMYHarmony Biosciences Holdings, Inc.
ITCIIntra-Cellular Therapies, Inc.
IRWDIronwood Pharmaceuticals, Inc.
JAZZJazz Pharmaceuticals plc
NBIXNeurocrine Biosciences Inc.
OPTNOptiNose, Inc.
OGNOrganon & Co.
PCRXPacira Biosciences, Inc.
RVNCRevance Therapeutics, Inc.
SUPNSupernus Pharmaceuticals, Inc.
TEVATeva Pharmaceutical Industries Limited
VTRSViatris, Inc.
XERSXeris Pharmaceuticals, Inc.